Daa Pangenotypic Epclusa denied as experimental or investigational by Humana?

Humana's specific coverage criteria for daa pangenotypic epclusa are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Issued an Experimental Denial for Epclusa

Epclusa (sofosbuvir/velpatasvir) is FDA-approved for treatment of chronic hepatitis C in adults and pediatric patients meeting the age and weight criteria listed in its prescribing label. An "experimental" or "investigational" denial from Humana is therefore surprising for a standard, on-label use — and it is almost always a strong candidate for reversal on appeal.

Humana's clinical coverage policies define what the insurer considers experimental or investigational, typically requiring that a treatment lack sufficient peer-reviewed evidence or regulatory approval for the indication being treated. Because Epclusa carries FDA approval for all major hepatitis C genotypes, any denial coded as experimental for an on-label use is likely based on a policy-application error, a missing clinical detail in the prior-authorization submission, or an off-label indication that was not clearly addressed.

## Federal Appeal Framework

• ACA Section 2719 / external review: Non-grandfathered plans must offer independent external review by an accredited IRO. The standard deadline is roughly four months from the denial; urgent cases may qualify for expedited review within approximately 72 hours. Confirm the precise deadline on your Explanation of Benefits.
• ERISA Section 503: Employer-sponsored plans must provide a full-and-fair review, including written notice of the specific criteria applied and an opportunity to submit additional clinical evidence.

## Concrete Appeal Steps and Timeline

1. Request the denial letter and the specific policy language Humana used to classify Epclusa as experimental. 2. Download Humana's current hepatitis C or DAA medical/coverage policy, noting the evidence-review date and approval criteria. 3. File a Level 1 internal appeal within the plan-stated deadline (often 180 days from denial). 4. If denied again, escalate to external review before the window on your denial notice closes.

## Documentation to Gather

• Diagnosis confirmation: Hepatitis C genotype report, quantitative viral load, and liver biopsy or elastography results establishing fibrosis stage.
• Indication match: Prescriber attestation that the use falls within Epclusa's FDA-approved indication as described in the current prescribing label.
• Prior-treatment history: Dates and outcomes of any previous hepatitis C therapies, supporting that this is not an unproven experimental approach for this patient.
• Clinical severity: Chart documentation of hepatic function and disease progression.
• Prescriber medical-necessity letter: Explicit statement that the prescribed use is on-label and supported by the relevant professional society guidelines (e.g., the applicable AASLD/IDSA guidance on hepatitis C management).

## Criteria-Mapping Structure

Obtain (a) the FDA-approved prescribing information for Epclusa and (b) Humana's published investigational/experimental policy and hepatitis C coverage policy. For each criterion Humana cites as unmet, provide the corresponding chart evidence and the regulatory or guideline reference showing the use is standard-of-care. A clear, point-by-point rebuttal significantly increases the likelihood of reversal.